Topic:

Companion Diagnostics

Latest Headlines

Latest Headlines

Roche and Merck KGaA team on a multicancer companion diagnostic test

Roche's Ventana Medical Systems will develop a companion diagnostic test with Germany's Merck KGaA that can be used for many different cancer types.

Roche lends Dx tech to Ferring for an infertility treatment

Roche is lending its diagnostic technology to Ferring Pharmaceuticals to develop a personalized treatment for female infertility.

Cancer Dx company Definiens adds $20.4M venture round

Definiens secured financing to grow its existing imaging-analysis business and to expand into tissue diagnostics. New investor Wellington Partners led the €15 million ($20.4 million) financing and joined the board.

NanoString to produce companion test for Celgene's blockbuster cancer drug Revlimid

Seattle's NanoString Technologies stands to make up to $45 million if it can come up with a successful companion diagnostic test to screen for a subset of lymphoma patients who will benefit from Celgene's blockbuster drug Revlimid.

Almac at ASCO: Dx spots ovarian cancer patients for whom Roche's Avastin would hurt

Almac Group saved some stellar news for the 2014 ASCO Annual Meeting in Chicago. The U.K. life sciences contract manufacturer said it validated a new diagnostic test that spots a subset of ovarian cancer patients with greater survival odds following standard chemotherapy who should avoid a specific Roche drug. 

Qiagen and Lilly continue successful string of diagnostics partnerships

Qiagen and Eli Lilly have joined forces for their fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer.

Qiagen and Lilly pair in their 4th cancer companion Dx project

Qiagen and Eli Lilly have clicked well enough in previous companion diagnostics development projects that they're signing up for a fourth go-around.

FDA OK's Qiagen companion Dx for use with Amgen colon cancer drug

Qiagen gained FDA approval for a companion diagnostic test that will help spot patients with metastatic colorectal cancer who might benefit most from Amgen's drug Vectibix. The regulatory milestone represents another advance in the Dutch company's growing focus on personalized medicine.

Abbott commits to companion Dx development for a promising Idera drug

Abbott Laboratories will develop a companion diagnostic test for a lymphoma/autoimmune drug now in clinical testing at Idera Pharmaceuticals.

Qiagen dials up sales as HPV competition heats up

Qiagen reported adjusted net income of $53.7 million on sales of $317.4 million in the first quarter. Net sales rose 4.5% year-over-year, and net income was up 11.6% at constant exchange rates.